Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.1
3.7
Journals
Pathogens
Special Issues
Antiviral Drugs in the Time of COVID-19
share announcement

Antiviral Drugs in the Time of COVID-19

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Viral Pathogens".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 4297

Special Issue Editors

Dr. Francisco Epelde

E-Mail Website
Guest Editor
Internal Medicine Department, Hospital de Sabadell, University Autonoma of Barcelona, Parc Tauli, 08208 Barcelona, Spain
Interests: heart failure; atriall fibrillation; ischemic cardiopathy; hospital administration
Special Issues, Collections and Topics in MDPI journals
Dr. Grigore Mihaescu

E-Mail Website
Guest Editor
Department of Microbiology, Immunology and Virology, Faculty of Biology, University of Bucharest, Bucharest, Romania
Interests: virology; immunology; antibiotic resistance of bacteria

Special Issue Information

Dear Colleagues,

The coronavirus disease 2019 (COVID-19) pandemic caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an unprecedented demand to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and the amount of clinical data generated by the large number of people being infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. This Special Issue is intended to provide the reader with an update on the current status of antiviral treatment in cases of SARS-CoV-2 infection. 

Dr. Francisco Epelde
Dr. Grigore Mihaescu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antiviral
  • COVID-19 infection
  • COVID-19 treatment

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1814 KiB  
Article
Melastoma malabathricum L. Suppresses Neutrophil Extracellular Trap Formation Induced by Synthetic Analog of Viral Double-Stranded RNA Associated with SARS-CoV-2 Infection
by Tse-Hung Huang, Pei-Wen Hsieh, Tsu-Jung Chen, Hui-Ju Tsai, Ju-Chien Cheng, Hsiang-Ruei Liao, Shun-Li Kuo and Ching-Ping Tseng
Pathogens 2023, 12(2), 341; https://doi.org/10.3390/pathogens12020341 - 17 Feb 2023
Cited by 1 | Viewed by 1719
Abstract
Platelet hyper-reactivity and neutrophil extracellular trap (NET) formation contribute to the development of thromboembolic diseases for patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study investigated the pathophysiological effects of SARS-CoV-2 surface protein components and the viral double-stranded RNA (dsRNA) [...] Read more.
Platelet hyper-reactivity and neutrophil extracellular trap (NET) formation contribute to the development of thromboembolic diseases for patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study investigated the pathophysiological effects of SARS-CoV-2 surface protein components and the viral double-stranded RNA (dsRNA) on platelet aggregation and NET formation. Traditional Chinese medicine (TCM) with anti-viral effects was also delineated. The treatment of human washed platelets with SARS-CoV-2 spike protein S1 or the ectodomain S1 + S2 regions neither caused platelet aggregation nor enhanced agonists-stimulated platelet aggregation. Moreover, NET formation can be induced by polyinosinic-polycytidylic acid (poly(I:C)), a synthetic analog of viral dsRNA, but not by the pseudovirus composed of SARS-CoV-2 spike, envelope, and membrane proteins. To search for TCM with anti-NET activity, the plant Melastoma malabathricum L. which has anticoagulant activity was partially purified by fractionation. One of the fractions inhibited poly(I:C)-induced NET formation in a dose-dependent manner. This study implicates that SARS-CoV-2 structural proteins alone are not sufficient to promote NET and platelet activation. Instead, dsRNA formed during viral replication stimulates NET formation. This study also sheds new insight into using the active components of Melastoma malabathricum L. with anti-NET activity in the battle of thromboembolic diseases associated with SARS-CoV-2 infection. Full article
(This article belongs to the Special Issue Antiviral Drugs in the Time of COVID-19)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 311 KiB  
Review
COVID-19 Treatment—Current Status, Advances, and Gap
by Chian Ho and Ping-Chin Lee
Pathogens 2022, 11(10), 1201; https://doi.org/10.3390/pathogens11101201 - 18 Oct 2022
Cited by 8 | Viewed by 2184
Abstract
COVID-19, which emerged in December 2019, was declared a global pandemic by the World Health Organization (WHO) in March 2020. The disease was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has caused millions of deaths worldwide and caused social and [...] Read more.
COVID-19, which emerged in December 2019, was declared a global pandemic by the World Health Organization (WHO) in March 2020. The disease was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has caused millions of deaths worldwide and caused social and economic disruption. While clinical trials on therapeutic drugs are going on in an Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership collaboration, current therapeutic approaches and options to counter COVID-19 remain few. Therapeutic drugs include the FDA-approved antiviral drugs, Remdesivir, and an immune modulator, Baricitinib. Hence, therapeutic approaches and alternatives for COVID-19 treatment need to be broadened. This paper discusses efforts in approaches to find treatment for COVID-19, such as inhibiting viral entry and disrupting the virus life cycle, and highlights the gap that needs to be filled in these approaches. Full article
(This article belongs to the Special Issue Antiviral Drugs in the Time of COVID-19)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop